Approach to Constipation and its Management Melissa G. Morgan, D.O.
-
Upload
lester-clarke -
Category
Documents
-
view
217 -
download
0
Transcript of Approach to Constipation and its Management Melissa G. Morgan, D.O.
![Page 1: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/1.jpg)
![Page 2: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/2.jpg)
Approach to Constipation and its
Management
Melissa G. Morgan, D.O.
![Page 3: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/3.jpg)
![Page 5: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/5.jpg)
Constipation
• Symptom based disorder– Bloating– Hard stools– Difficult stool passage– Sensation of incomplete evacuation– Frequent straining
![Page 6: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/6.jpg)
Constipation
• Common condition with 15% prevalence in North America and female to male ratio 2.2:1
• Symptoms increase with age > 65• Primary causes
– Functional (most common) include IBS-C– Defecation disorders
• Pelvic floor dyssynergia• Excessive perineal descent• Mechanical obstruction
– Slow transit (least common)
![Page 7: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/7.jpg)
7
![Page 8: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/8.jpg)
8
![Page 9: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/9.jpg)
Initial Testing
• CBC • TSH if there are other symptoms
consistent with hypothyroidism• Colonoscopy if any alarm features present
- blood in stool, anemia, weight loss, or if age appropriate screening has not already been performed
9
![Page 10: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/10.jpg)
Functional• IBS-C
– Recurrent abdominal pain at least 3 days/month during the last 3 months with onset ≥ 6 months prior
– Improvement with defecation, change in stool frequency or change in stool appearance or form
• Chronic constipation– Straining during at least 25% of defecations– Sensation of incomplete emptying for at least 25%
defecations– Sensation of anorectal obstruction for at least 25% of
defecations– Need to use manual maneuvers to facilitate evacuation for at
least 25% of defecations– < 3 defecations per week
![Page 11: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/11.jpg)
Functional
• Treatment options– Fiber supplementation, exercise, healthy diet, osmotic
laxative– May use stimulant laxative no more than 2-3 times per
week– Rx medications
• Lubiprostone- chloride channel activator • increases intestinal fluid secretion thereby increasing motility
in the intestine• Linaclotide-guanylate cyclase agonist
• Increases cGMP which stimulates secretion of chloride and bicarbonate which increases intestinal fluid, accelerates transit and reduces intestinal pain
![Page 12: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/12.jpg)
Lubiprostone
• Take with food and water• Chronic idiopathic constipation
- 24mcg BID• IBS-C (women)
- 8mcg BID• Opioid induced constipation (non-cancer)
- 24mcg BID
12
![Page 13: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/13.jpg)
Lubiprostone
• Adverse reactions- Nausea- Diarrhea- Headache- Dyspnea
• Pregnancy category C• Unknown if excreted in human breast milk;
not in animals- Infants should be monitored for diarrhea
13
![Page 14: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/14.jpg)
Linaclotide
• Take on empty stomach at least 30 minutes prior to a meal
• Chronic idiopathic constipation- 145mcg daily
• IBS-C- 290mcg daily
14
![Page 15: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/15.jpg)
Linaclotide
• Adverse reactions- Diarrhea- Abdominal pain- Flatulence
• Pregnancy category C• Unknown if excreted in human breast milk
15
![Page 16: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/16.jpg)
Pelvic Floor Dyssynergia
• Accounts for 1/3 of constipation in the community• Likely acquired behavior disorder
- Increased muscle tension from anxiety or stress- Sexual abuse is reported in 22% of women with defecation
disorders• Puborectalis muscles and external anal sphincter must
relax• Diagnosed with anorectal manometry and balloon
expulsion test- evidence that pelvic floor retraining is superior to
laxatives for defecatory disorders- ~70% have improvement
• Biofeedback therapy
![Page 17: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/17.jpg)
![Page 18: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/18.jpg)
18
![Page 20: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/20.jpg)
Opioid Induced Constipation
• Most common reported side effect of opioid use in 41% of patients
• Mu-opioid receptors- inhibition of propulsive activity of intestine and slow
intestinal transit
20
![Page 21: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/21.jpg)
Methylnaltrexone Bromide (Relistor)
• Inhibits opioids from binding to mu-receptors in GI tract
• Does not cross blood brain barrier- Doesn’t interfere with centrally located
receptors
21
![Page 22: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/22.jpg)
Methylnaltrexone Bromide
• Dosing• Single vial dosing (12mg) and pre-filled
syringe (8mg and 12mg)- Chronic non-cancer pain
- 12mg SQ daily (0.6mL)
- Advanced illness- weight based and every other day dosing prn- no studies past 4 months
• Cut dose in half for creatine clearance <30mL/min
22
![Page 23: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/23.jpg)
Methylnaltrexone Bromide
• Category C• Unsure if passes into breast milk• Can cause opioid withdrawal in fetus due
to immature BBB• ADRs
- abdominal pain, nausea, diarrhea, hyperhidrosis
23
![Page 24: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/24.jpg)
Naloxegol (Movantik)• Peripherally acting mu-opioid receptor
antagonist; for use in chronic non-cancer pain
• Take on empty stomach 1 hour prior to first meal or 2 hours after
• 25mg PO daily; also comes in 12.5mg• First BM within 6-12 hours• Same ADRs as SQ injection• Category C
24
![Page 25: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/25.jpg)
Summary
• Many different causes of constipation and treatment is based on underlying cause
• Know when to move on from fiber and OTC medications
• Pelvic floor dyssynergia is extremely common in up to 1/3 of those with constipation in the community and can be treated with biofeedback
![Page 26: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/26.jpg)
Summary
• Opioid induced constipation is managed differently than other forms of constipation
• Refer if any alarm features or if not comfortable moving beyond OTC medications
26
![Page 27: Approach to Constipation and its Management Melissa G. Morgan, D.O.](https://reader036.fdocuments.in/reader036/viewer/2022062323/5697bfb51a28abf838c9dafc/html5/thumbnails/27.jpg)
27